NCT05315479View on ClinicalTrials.gov

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

PHASE4TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Post Operative Pain
Interventions
DRUG

N1539

Once daily

Trial Locations (3)

35660

Research Center, Sheffield

84107

Research Center, Salt Lake City

93301

Research Center, Bakersfield

Sponsors

Lead Sponsor

Baudax Bio
All Listed Sponsors
lead

Baudax Bio

INDUSTRY

NCT05315479 - Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery | Biotech Hunter | Biotech Hunter